Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa open-label study of VG161 alone or with apatinib in advanced bone sarcomas
ChiCTR2100049548Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of VG161 and Rivoceranib in osteosarcoma (OS), Ewing sarcoma of bone, chordoma and 1 more (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 3 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
VG161Rivoceranib
03
Conditions
osteosarcoma (OS)Ewing sarcoma of bonechordomachondrosarcoma
Beyond the preview
Go deeper on ChiCTR2100049548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049548.